Business
Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
- 15 abstracts accepted for presentation showcasing LIVMARLI data from ALGS and PFIC programs - LIVMARLI PFIC primary analysis from MARCH study awarded
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- 15 abstracts accepted for presentation showcasing LIVMARLI data from ALGS and PFIC programs\n\n\n- LIVMARLI PFIC primary analysis from MARCH study awarded prestigious Gerard Odell Prize for Excellence in Pediatric Hepatology Research\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that data from its LIVMARLI® (maralixibat) oral solution studies as well as data from real- world experience will be presented at the upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) annual meeting taking place October 4-7, 2023, in San Diego, California.\n\n\nHighlighted below are the titles that have been accepted for presentation during the meeting. The abstracts are available via the NASPGHAN website. Full analyses will be available following their presentation within the Publications & Presentations section on Mirum’s website.\n\n\nOral Presentation\n\n\nAbstract 531: Efficacy and safety of maralixibat in patients with progressive familial intrahepatic cholestasis (MARCH): A randomized placebo-controlled phase 3 study\nSaturday, October 7, 2023, between 10:30am-12:00pm during the ‘Spill the Tea on Liver Disease’ session\n**Gerard Odell Prize for Excellence in Pediatric Hepatology Research Recipient**\n\n\nPoster Presentations\n\n\nAlagille syndrome (ALGS)\n\n\nAbstract 69: Maralixibat for the treatment of severe xanthomas in two children with Alagille syndrome\nThursday, October 5, 2023, between 5:00-7:00 p.m. PT during Poster Session I\n\n\nAbstract 71: Maralixibat persistency and adherence for the treatment of cholestatic pruritus in Alagille Syndrome: Real-world experience in the United States\nThursday, October 5, 2023, between 5:00-7:00 p.m. PT during Poster Session I\n\n\nAbstract 72: Maralixibat impact on concomitant medication use for the treatment of cholestatic pruritus in Alagille syndrome: Real-world experience in the United States\nThursday, October 5, 2023, between 5:00-7:00 p.m. PT during Poster Session I\n\n\nAbstract 88: Impact of maralixibat on cholestatic pruritus in young adults aged 16 years and older with Alagille syndrome\nThursday, October 5, 2023, between 5:00-7:00 p.m. PT during Poster Session I\n\n\nAbstract 89: Maralixibat, an ileal bile acid transporter inhibitor, delays the need for liver transplant in patie...